Your browser version may not work well with NCBI's Web applications. More information here...
1: Mymensingh Med J. 2005 Jan;14(1):71-4.Links
Erratum in:
Mymensingh Med J. 2005 Jul;14(2):228.

Placebo controlled trial of methotrexate in systemic sclerosis.

Das SN, Alam MR, Islam N, Rahman MH, Sutradhar SR, Rahman S, Khan GK, Rahim A, Haq SA.

Sir Salimullah Medical College, Dhaka.

Eighteen adult patients of systemic sclerosis were included in this prospective study from Rheumatology Clinic of Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka during the period of July 1997 to December 1999 to observe the effectiveness of treatment with methotrexate (MTX) versus placebo. Among the eighteen patients 9 patients were randomly assigned to MTX and 9 to placebo therapy. Nine patients were dropped out (6 in placebo and 3 in the MTX group), because of toxicity and non-compliance. Clinical improvement following treatment was observed in 33.33% of the patient in MTX group but none in placebo group, but this difference was not statistically significant. Anorexia, nausea and occasional vomiting were common side effects in MTX group and subsided in most cases with the passage of time despite the continuation of therapy.

PMID: 15695960 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Methotrexate (Rheumatrex® , Trexall® )

    Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments. Methotrexate is also used along with rest, physica...

  • Source: AHFS Consumer Medication Information